- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06892977
Картирование стресса и боли взаимодействия (G072323N) (STRAIN)
STRAIN (STRessinpAIN): A Comprehensive Mapping of Stress System Interactions With Pain and Their Contribution to Extent and Chronification of Musculoskeletal Pain
The over-arching goal of this observational (case-control, with a cross-sectional and longitudinal arm) study is to comprehensively map stress system (dys)function (including reactivity and recovery) in people with primary musculoskeletal (MSK) pain and a pain-free control group.
- The primary objective is to characterize stress systems functioning and their relation to pain in individuals with subacute versus chronic, and localized versus widespread MSK pain, and compare to pain-free controls.
- The secondary objective is to define the contribution of stress system functioning to trajectories of MSK pain, including pain chronification or recovery from pain.
Researchers will compare primary musculoskeletal pain groups with pain-free controls. Participants will:
- Fill out online questionnaires.
- Provide a sample of hair and saliva to assess chronic and acute stress hormone levels, respectively. Saliva samples will be collected both in the lab and at home.
- Be subject to psychophysiological monitoring.
- Partake in quantitative sensory testing measuring pain thresholds, tolerances and pain modulation of pressure and heat. These tests will be repeated twice: before and after an acute-stress induction task.
- Partake in a series of stress-inducting tasks.
- Be subject to MRI-scans of the brain, including structural and functional MR acquisitions (e.g., during rest and during pain inductions).
Participants will be invited for a second session of the same assessments six months later to observe possible connection between pain trajectory and stress system (dys)function.
Обзор исследования
Статус
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Места учебы
-
-
-
Ghent, Бельгия, 9000
- Ghent University, Department of Rehabilitation Sciences
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Study population is a community sample.
Описание
Inclusion Criteria:
• Participants aged 18 to 55 years with a BMI between 17 and 35 kg/m², who are proficient in the Dutch language and do not meet the exclusion criteria listed below
Exclusion Criteria:
- Body weight >150 kg (maximum weight for the MRI scanner).
- Postmenopausal individuals.
- Use of hormone replacement therapy.
- Current or history of severe psychiatric, neurological (related to the brain, spinal cord, or nerves), endocrine (related to the hormonal system), or cardiovascular (related to the heart and blood vessels) conditions (e.g., cancer, cardiovascular disease, epilepsy, diabetes, etc.).
- History of spinal surgery, spinal trauma, severe spinal deformities, or neurogenic back pain.
- Having a severe communicative or cognitive disorder.
- Use of medication that is not stable for at least 1 month prior to the test session.
- Regular drug use (≥1 time per week).
- Contraindications for MRI (such as claustrophobia, implanted electronic devices like a pacemaker, metal splinters in the body, etc.).
- Currently pregnant or have been pregnant in the past year.
- Breastfeeding.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: OTHER
- Временные перспективы: CROSS_SECTIONAL
Когорты и вмешательства
Группа / когорта |
|---|
|
fibromyalgia
Proof of a primary fibromyalgia diagnosis with chronic widespread pain by a specialist-doctor, with an average pain intensity of ≥2/10 on a Visual Analogue Scale, and with pain-related disability indicated by a score of ≥14/70 on the Pain Disability Index. |
|
chronic low back pain
Chronic primary (non-specific) low back pain with primary onset ≥6 months ago, with an average pain intensity of ≥2/10 on a Visual Analogue Scale, and with pain-related disability indicated by a score of ≥14/70 on the Pain Disability Index. |
|
subacute low back pain
Non-specific low back pain with primary onset <3 months ago, with an average pain intensity of ≥2/10 on a Visual Analogue Scale, and with pain-related disability indicated by a score of ≥14/70 on the Pain Disability Index. |
|
pain-free/healthy control
Exclusion criteria include current pain (>0 on a Visual Analogue Scale); a pain condition in the last 6 months for which treatment was sought; history of a chronic pain syndrome. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Quantitative sensory testing - pressure pain threshold
Временное ограничение: At baseline
|
Determination of mechanical pain sensitivity with a digital pressure algometer, recorded in kg. |
At baseline
|
|
Quantitative sensory testing - heat pain suprathreshold
Временное ограничение: At baseline
|
Determination of the mean of heat pain threshold and heat pain tolerance with TSA-2, recorded in °C. |
At baseline
|
|
Quantitative sensory testing - conditioned pain modulation
Временное ограничение: At baseline
|
Determination of conditioned pain modulation with a parallel protocol, with test stimulus and conditioning stimulus equal to the heat pain suprathreshold temperature. Pain will be scored on a verbal rating scale 0-100. |
At baseline
|
|
Quantitative sensory testing - temporal summation of pain
Временное ограничение: At baseline
|
Determination of temporal summation of pain with a tonic protocol. Heat stimuli will be applied for two minutes, with the temperature equal to the heat pain suprathreshold. Pain will be scored on a verbal rating scale 0-100. |
At baseline
|
|
Task-based functional MRI - experimental pain induction task
Временное ограничение: At baseline
|
This type of functional MRI-scanning will allow to capture acute brain responses to (painful) heat stimuli and processes of pain modulation. |
At baseline
|
|
Salivary cortisol concentration
Временное ограничение: At baseline
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse cortisol concentration; providing information about the hypothalamus-pituitary-adrenal-axis functioning. |
At baseline
|
|
Salivary alpha-amylase concentration
Временное ограничение: At baseline
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse alpha-amylase concentrations; which gives information about the autonomic nervous system functioning. |
At baseline
|
|
Salivary oxytocin concentration
Временное ограничение: At baseline
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse oxytocin concentrations; providing information about the oxytocinergic system. |
At baseline
|
|
Heart rate
Временное ограничение: At baseline
|
Heart rate, the number of times the heart beat within a certain period, will be measured continuously using ECG (electrocardiogram), providing information on the autonomic nervous system. |
At baseline
|
|
Heart rate variability
Временное ограничение: At baseline
|
Heart rate variability (HRV), the fluctuations in time between heart beats, will be measured continuously using ECG. Both time domain and frequency domain of HRV will be examined; providing information on the autonomic nervous system. |
At baseline
|
|
Skin conductance
Временное ограничение: At baseline
|
Skin conductance reflects sweat gland activity and will be measured continuously; providing information on the autonomic nervous system. |
At baseline
|
|
Skin temperature
Временное ограничение: At baseline
|
Skin temperature, the measurement of the temperature at the skin's surface will be measured continuously; providing information on the autonomic nervous system. |
At baseline
|
|
Respiration rate
Временное ограничение: At baseline
|
Respiration rate, the number of breaths taken per minute will be measured continuously; providing information on the autonomic nervous system. |
At baseline
|
|
Blood pressure
Временное ограничение: At baseline
|
Blood pressure, the force exerted by circulating blood on the walls of blood vessels, will be measured using non-continuously; providing information on the autonomic nervous system. |
At baseline
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Visual Analogue Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of momentary pain, unpleasantness and stress on a VAS scale ranging from 0-100 |
At baseline and at the 6-month follow-up
|
|
Pain Disability Index - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of pain-related interference in daily activities, recorded on a 0-70 scale |
At baseline and at the 6-month follow-up
|
|
Pain Catastrophizing Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of catastrophic thinking related to pain, recorded on a scale of 0-52. |
At baseline and at the 6-month follow-up
|
|
Pain Vigilance and Awareness Questionnaire - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of attention and awareness to pain, recorded on a 0-80 scale. |
At baseline and at the 6-month follow-up
|
|
General Perceived Recovery - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
11-point scale to rate perceived recovery from - 5 (vastly worse), through 0 (no change) to + 5 (greatly improved), to assess recovery or persistence of low back pain |
At baseline and at the 6-month follow-up
|
|
Pain Anxiety Symptoms Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of fear and anxiety associated with pain, recorded on a 0-100 scale. |
At baseline and at the 6-month follow-up
|
|
Positive and Negative Affect Schedule - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of positive and negative affect levels. Total scores for positive and negative affect range for 10-50 separately. |
At baseline and at the 6-month follow-up
|
|
Brief Resilience Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of the ability to recover from stress, recorded on a 5-point Likert scale. This questionnaire contains 6 items. |
At baseline and at the 6-month follow-up
|
|
Intolerance of Uncertainty Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of intolerance to uncertainty, recorded on a scale of 1-5 for each item, with 12 items in total. |
At baseline and at the 6-month follow-up
|
|
Stress Mindset Measure - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Evaluation of beliefs about the nature of stress (enhancing vs. debilitating), recorded on a scale of 0-4 for each item, with 8 items in total. |
At baseline and at the 6-month follow-up
|
|
Perceived Stress Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of perceived stress over the past month, recorded on a scale of 0-40. |
At baseline and at the 6-month follow-up
|
|
Hospital Anxiety and Depression Scale - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Assessment of anxiety and depression symptoms, recorded on a scale of 0-21 for anxiety and depression subscales separately. |
At baseline and at the 6-month follow-up
|
|
Childhood Trauma Questionnaire - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of childhood trauma experiences. A shortened version will be used with scores ranging from 0-25. Emotional abuse, physical abuse, and neglect components will be assessed. |
At baseline and at the 6-month follow-up
|
|
Pittsburgh Sleep Quality Index - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Measurement of sleep quality over the past month. A shortened version will be used with scores ranging from 0-12. Component 1-4 will be scored. |
At baseline and at the 6-month follow-up
|
|
Gender and Pain Questionnaire - Self-reported
Временное ограничение: At baseline and at the 6-month follow-up
|
Collection of scales of measures for gender conceptualization, gender identity and gendered pain beliefs |
At baseline and at the 6-month follow-up
|
|
T1 weighted anatomical MRI data
Временное ограничение: At baseline and at the 6-month follow-up
|
Through Magnetization Prepared-Rapid Gradient Echo, macro-structural properties of grey matter, such as surface area, cortical thickness or volume will be characterized. |
At baseline and at the 6-month follow-up
|
|
Resting state functional MRI
Временное ограничение: At baseline and at the 6-month follow-up
|
This type of MRI-scan will allow us to evaluate functional connectivity of the brain. |
At baseline and at the 6-month follow-up
|
|
Diffusion weighted MRI data
Временное ограничение: At baseline and at the 6-month follow-up
|
Diffusion weighted MR imaging will provide insights in microstructural properties of white matter (i.e., factional anisotropy, mean diffusivity, etc.). |
At baseline and at the 6-month follow-up
|
|
Pseudo-Continuous Arterial Spin Labeling - MRI
Временное ограничение: At baseline and at the 6-month follow-up
|
This type of MRI will provide information on brain blood perfusion parameters. |
At baseline and at the 6-month follow-up
|
|
Quantitative sensory testing - pressure pain threshold (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Determination of mechanical pain sensitivity with a digital pressure algometer, recorded in kg. |
At the 6-month follow-up
|
|
Quantitative sensory testing - heat pain suprathreshold (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Determination of the mean of heat pain threshold and heat pain tolerance with TSA-2, recorded in °C. |
At the 6-month follow-up
|
|
Quantitative sensory testing - conditioned pain modulation (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Determination of conditioned pain modulation with a parallel protocol, with test stimulus and conditioning stimulus equal to the heat pain suprathreshold temperature. Pain will be scored on a verbal rating scale 0-100. |
At the 6-month follow-up
|
|
Quantitative sensory testing - temporal summation of pain (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Determination of temporal summation of pain with a tonic protocol. Heat stimuli will be applied for two minutes, with the temperature equal to the heat pain suprathreshold. Pain will be scored on a verbal rating scale 0-100. |
At the 6-month follow-up
|
|
Task-based functional MRI - experimental pain induction task (at follow-up)
Временное ограничение: At the 6-month follow-up
|
This type of functional MRI-scanning will allow to capture acute brain responses to (painful) heat stimuli and processes of pain modulation. |
At the 6-month follow-up
|
|
Salivary cortisol concentration (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse cortisol concentrations; providing information about the hypothalamus-pituitary-adrenal-axis functioning. |
At the 6-month follow-up
|
|
Salivary alpha-amylase concentration (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse alpha-amylase concentrations; providing information about the autonomic nervous system functioning. |
At the 6-month follow-up
|
|
Salivary oxytocin concentration (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Saliva samples will be taken, with a swab under the tongue for 2 minutes to analyse oxytocin concentrations; providing information on the oxytocinergic system. |
At the 6-month follow-up
|
|
Heart rate (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Heart rate, the number of times the heart beat within a certain period, will be measured with ECG continuously, and is part of the autonomic nervous system. |
At the 6-month follow-up
|
|
Heart rate variability (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Heart rate variability, the fluctuations in time between heart beats, will be measured with ECG continuously. Both time domains and frequency domains of HRV will be examined. This parameter is part of the autonomic nervous system. |
At the 6-month follow-up
|
|
Skin conductance (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Skin conductance reflects sweat gland activity and will be measured continuously; providing information on the autonomic nervous system. |
At the 6-month follow-up
|
|
Skin temperature (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Skin temperature, the measurement of the temperature at the skin's surface will be measured continuously; providing information on the autonomic nervous system. |
At the 6-month follow-up
|
|
Respiration rate (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Respiration rate, the number of breaths taken per minute will be measured continuously; providing information on the autonomic nervous system. |
At the 6-month follow-up
|
|
Blood pressure (at follow-up)
Временное ограничение: At the 6-month follow-up
|
Blood pressure, the force exerted by circulating blood on the walls of blood vessels, will be measured using non-continuously; providing information on the autonomic nervous system. |
At the 6-month follow-up
|
Соавторы и исследователи
Спонсор
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- Боль в пояснице
- Окситоцин
- Фибромиалгия
- Хроническая распространенная боль
- Скелетно-мышечная боль
- Обработка боли
- Стресс-реактивность
- Вегетативная нервная система (ВНС)
- Стрессовая система
- Боль в хронификации
- Нейронные корреляты боли
- Восстановление стресса
- Гипоталамус-гипофизарная адренальная ось (ось HPA)
- Хроническая локализованная боль
Дополнительные соответствующие термины MeSH
- Боль
- Неврологические проявления
- Заболевания опорно-двигательного аппарата
- Заболевания нервной системы
- Мышечные заболевания
- Нервно-мышечные заболевания
- Ревматические заболевания
- Боль в спине
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Скелетно-мышечная боль
- Фибромиалгия
- Хроническая боль
- Боль в пояснице
Другие идентификационные номера исследования
- ONZ-2024-0391
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Ghent University will be the data controller. The collected data can only be shared upon request and after finalization of the predetermined statistical analyses and publication of the results. Identifiable data will not be shared. Data sharing is only permitted if all involved parties agree, and if a Data Sharing Agreement is signed.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .